Search Orphan Drug Designations and Approvals
-
Generic Name: | dexamethasone intravitreal implant | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Trade Name: | Ozurdex | ||||||||||||||||
Date Designated: | 09/11/1998 | ||||||||||||||||
Orphan Designation: | Treatment of non-infectious ocular inflammation of the posterior segment in patients with intermediate, posterior, and panuveitis | ||||||||||||||||
Orphan Designation Status: | Designated/Approved | ||||||||||||||||
Sponsor: |
Allergan 2525 Dupont Drive Irvine, California 92623 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
||||||||||||||||
Marketing approved: |
|||||||||||||||||
1 | Generic Name: | dexamethasone intravitreal implant |
---|---|---|
Trade Name: | Ozurdex | |
Marketing Approval Date: | 09/24/2010 | |
Approved Labeled Indication: | For treatment of non-infectious uveitis affecting the posterior segment of the eye | |
Exclusivity End Date: | 09/24/2017 | |
Exclusivity Protected Indication* : | ||
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-